“Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway”, NJPS, vol. 40, no. 2, Apr. 2026, doi: 10.54548/.